HILPDA and autoimmune disease: Thus, HIG2-9-4 peptide-specific CTLs should not induce unintended immunological responses to normal cells, such as those associated with autoimmune diseases, even if this novel and unique peptide induces strong immune responses against HIG2-expressing RCC.